A newly published cache of CRLs includes six novel oncology drugs.
ApexOnco Front Page
Recent articles
The deal for ISB 2001 is worth $700m up front.
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
The group reports responses with its CD123-targeting ADC, but cash is running short.
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.